Edwards Lifesciences Corp (EW)
87.61
-1.00
(-1.13%)
USD |
NYSE |
Apr 25, 11:41
Edwards Lifesciences Cash from Financing (Quarterly): -413.20M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -413.20M |
| September 30, 2023 | -143.30M |
| June 30, 2023 | 52.10M |
| March 31, 2023 | -206.60M |
| December 31, 2022 | -838.40M |
| September 30, 2022 | -69.90M |
| June 30, 2022 | -308.10M |
| March 31, 2022 | -368.10M |
| December 31, 2021 | -62.00M |
| September 30, 2021 | 39.00M |
| June 30, 2021 | -59.00M |
| March 31, 2021 | -274.30M |
| December 31, 2020 | 41.40M |
| September 30, 2020 | 34.00M |
| June 30, 2020 | 24.10M |
| March 31, 2020 | -586.40M |
| December 31, 2019 | 37.00M |
| September 30, 2019 | 34.40M |
| June 30, 2019 | -231.40M |
| March 31, 2019 | 44.40M |
| December 31, 2018 | -844.70M |
| September 30, 2018 | -56.70M |
| June 30, 2018 | -240.70M |
| March 31, 2018 | 40.90M |
| December 31, 2017 | -229.00M |
| Date | Value |
|---|---|
| September 30, 2017 | 20.30M |
| June 30, 2017 | 126.80M |
| March 31, 2017 | -391.30M |
| December 31, 2016 | 5.10M |
| September 30, 2016 | 63.80M |
| June 30, 2016 | 31.70M |
| March 31, 2016 | -369.10M |
| December 31, 2015 | -59.70M |
| September 30, 2015 | 23.60M |
| June 30, 2015 | -50.60M |
| March 31, 2015 | -71.90M |
| December 31, 2014 | 45.90M |
| September 30, 2014 | 48.70M |
| June 30, 2014 | -103.80M |
| March 31, 2014 | -143.80M |
| December 31, 2013 | 80.50M |
| September 30, 2013 | 68.60M |
| June 30, 2013 | -89.30M |
| March 31, 2013 | -24.90M |
| December 31, 2012 | -146.90M |
| September 30, 2012 | -0.50M |
| June 30, 2012 | -5.10M |
| March 31, 2012 | -3.10M |
| December 31, 2011 | -53.60M |
| September 30, 2011 | -97.20M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-838.40M
Minimum
Dec 2022
52.10M
Maximum
Jun 2023
-173.62M
Average
-69.90M
Median
Sep 2022
Cash from Financing (Quarterly) Benchmarks
| Stryker Corp | -286.00M |
| Boston Scientific Corp | 15.00M |
| Align Technology Inc | -350.28M |
| Abbott Laboratories | -2.052B |
| Steris PLC | -197.99M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 136.60M |
| Cash from Investing (Quarterly) | 14.10M |
| Free Cash Flow | 629.50M |
| Free Cash Flow Per Share (Quarterly) | 0.0577 |
| Free Cash Flow to Equity (Quarterly) | 34.80M |
| Free Cash Flow to Firm (Quarterly) | 35.00M |
| Free Cash Flow Yield | 1.18% |